BNBryan Ng

Bryan Ng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bryan Ng has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Richard Wade-Martins

    Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3QX, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK

    6 shared publications
  • Amanda J. Heslegrave

    UK Dementia Research Institute, Cruciform Building University College London London UK

    2 shared publications
  • Anne Hedegaard

    Department of Psychiatry, University of Oxford, Headington , Oxford OX3 7JX , UK

    2 shared publications
  • Dayne Beccano-Kelly

    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

    2 shared publications
  • Dennis Chan

    Department of Clinical Neurosciences, University of Cambridge , Cambridge CB2 0QQ , UK

    2 shared publications
  • Eleftheria Kodosaki

    UK Dementia Research Institute, Cruciform Building University College London London UK

    2 shared publications

Latest Publications

  • Open Access

    Aging‐related matrix metallopeptidase 10 and osteopontin levels are associated with pathology, cognitive decline, and age at onset in Alzheimer's disease

    by Bryan Ng, Eleftheria Kodosaki, Elena Veleva, Ashvini Keshavan, Jonathan M. Schott, Amanda J. Heslegrave, Nick C. Fox, Henrik Zetterberg

    INTRODUCTION: Aging is the strongest risk factor for Alzheimer's disease (AD) characterized by amyloid‐β (Aβ) plaques and tau tangles in the brain. We aim to compare biological aging‐related biomarkers among AD, non‐neurodegenerative control (NDC) and non‐AD neurodegenerative (Non‐AD) individuals to evaluate their clinical utility. METHODS: We included 137 participants (37 NDC, 67 AD, 33 Non‐AD) from the University College London (UCL) Dementia Research Centre and measured matrix metallopeptidase 10 (MMP‐10), osteopontin (OPN), neurofilament‐light, and glial fibrillary acidic protein in cerebrospinal fluid (CSF) in addition to Aβ/pTau and clinical parameters. RESULTS: Elevated MMP‐10 associated with poorer cognition and later onset specifically in AD, whereas elevated OPN associated with Aβ and tau pathology. MMP‐10 and OPN levels improved the differentiation of AD from NDC, and AD from Non‐AD, respectively. DISCUSSION: Our study provides evidence on potential clinical utility of CSF MMP‐10 and OPN in diagnosis and supports taking biological aging into consideration in AD research. Highlights: Elevated osteopontin and matrix metallopeptidase 10 (MMP‐10) levels in Alzheimer's disease (AD) cerebrospinal fluid. MMP‐10 levels are linked to age at onset and cognitive decline. Osteopontin levels are linked to AD pathologies in the cerebrospinal fluid. MMP‐10 levels improved discrimination of AD from non‐neurodegenerative controls. Osteopontin levels improved discrimination of AD from other neurodegenerative cases.


  • Open Access

    Aging-related matrix metallopeptidase 10 and osteopontin levels are associated with pathology, cognitive decline and age at onset in Alzheimer’s disease

    by Bryan Ng, Eleftheria Kodosaki, Elena Veleva, Ashvini Keshavan, Jonathan M. Schott, Amanda J. Heslegrave, Nick C. Fox, Henrik Zetterberg

    INTRODUCTION: Aging is the strongest risk factor for Alzheimer’s disease (AD) characterized by amyloid-β (Aβ) plaques and tau tangles in the brain. We aim to compare biological aging-related biomarkers among AD, non-neurodegenerative control (NDC) and non-AD neurodegenerative disease (Non-AD) individuals to evaluate their clinical utility. METHODS: We included 137 participants (37 NDC, 67 AD, 33 Non-AD) from the UCL Dementia Research Centre and measured matrix metallopeptidase 10 (MMP-10), osteopontin (OPN), neurofilament-light, and glial fibrillary acidic protein in cerebrospinal fluid (CSF) samples in addition to Aβ/pTau and clinical parameters. RESULTS: Elevated MMP-10 associated with poorer cognition and later onset specifically in AD, whereas elevated OPN associated with CSF Aβ and tau pathology. MMP-10 and OPN levels improved the differentiation of AD from NDC, and AD from Non-AD, respectively. DISCUSSION: Our study provides evidence on potential clinical utility of CSF MMP-10 and OPN in AD diagnosis and supports taking biological aging into consideration in AD research.

  • Open Access

    Know your brain aging to know your resilience in neurodegenerative diseases

    by Bryan Ng, Henrik Zetterberg

    This scientific commentary refers to ‘Brain aging rejuvenation factors in adults with genetic and sporadic neurodegenerative disease’, by Casaletto et al. (https://doi.org/10.1093/braincomms/fcae432).


  • Open Access

    Tau depletion in human neurons mitigates Aβ-driven toxicity

    by Bryan Ng, Jane Vowles, Féodora Bertherat, Ajantha Abey, Peter Kilfeather, Dayne Beccano-Kelly, M. Irina Stefana, Darragh P. O’bRien, Nora Bengoa-Vergniory, Phillippa J. Carling, et al.

    Alzheimer’s disease (AD) is an age-related neurodegenerative condition and the most common type of dementia, characterised by pathological accumulation of extracellular plaques and intracellular neurofibrillary tangles that mainly consist of amyloid-β (Aβ) and hyperphosphorylated tau aggregates, respectively. Previous studies in mouse models with a targeted knock-out of the microtubule-associated protein tau (Mapt) gene demonstrated that Aβ-driven toxicity is tau-dependent. However, human cellular models with chronic tau lowering remain unexplored. In this study, we generated stable tau-depleted human induced pluripotent stem cell (iPSC) isogenic panels from two healthy individuals using CRISPR-Cas9 technology. We then differentiated these iPSCs into cortical neurons in vitro in co-culture with primary rat cortical astrocytes before conducting electrophysiological and imaging experiments for a wide range of disease-relevant phenotypes. Both AD brain derived and recombinant Aβ were used in this study to elicit toxic responses from the iPSC-derived cortical neurons. We showed that tau depletion in human iPSC-derived cortical neurons caused considerable reductions in neuronal activity without affecting synaptic density. We also observed neurite outgrowth impairments in two of the tau-depleted lines used. Finally, tau depletion protected neurons from adverse effects by mitigating the impact of exogenous Aβ-induced hyperactivity, deficits in retrograde axonal transport of mitochondria, and neurodegeneration. Our study established stable human iPSC isogenic panels with chronic tau depletion from two healthy individuals. Cortical neurons derived from these iPSC lines showed that tau is essential in Aβ-driven hyperactivity, axonal transport deficits, and neurodegeneration, consistent with studies conducted in Mapt−/− mouse models. These findings highlight the protective effects of chronic tau lowering strategies in AD pathogenesis and reinforce the potential in clinical settings. The tau-depleted human iPSC models can now be applied at scale to investigate the involvement of tau in disease-relevant pathways and cell types.


  • Open Access

    iPSC‐derived cortical neurons of sporadic Alzheimer’s disease patients reflect their clinical vulnerability

    by Féodora Bertherat, Bryan Ng, Nora Bengoa‐Vergniory, Becky C. Carlyle, Richard Wade‐Martins

    Background: iPSC‐derived cortical neurons from sporadic Alzheimer’s Disease (AD) patients were used to compare cellulare phenotypes in response to AB or tau insults with clinical data of the individual patients.Method: We generated14 iPSC lines from sAD patients from the Deep and Frequent Phenotyping study, which has collected a battery of clinical data from early‐stage sAD patients. Phenotypes such as neurite loss, axonal branching or cytotoxicity were measured in iPSC‐derived cortical neurons following Amyloid Beta oligomer treatment.Result: Individual AD patient lines exhibit significantly different levels of neurite loss and decreased axonal branching due to Amyloid Beta. This differences is significantly correlated with clinical vulnerability of the individual patients.Conclusion: Differences in disease vulnerability in patients observed in clinic is reflected in patient iPSC lines when treated with Amyloid Beta.

  • Open Access

    Early striatal hyperexcitability in an in vitro human striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation

    by Quyen B. Do, Bryan Ng, Ricardo Marquez Gomez, Dayne Beccano-Kelly, Naroa Ibarra-Aizpura, Maria-Claudia Caiazza, Charmaine Lang, Jimena Baleriola, Nora Bengoa-Vergniory, Richard Wade-Martins

    Understanding medium spiny neuron (MSN) physiology is essential to understand motor impairments in Parkinson’s disease (PD) given the architecture of the basal ganglia. Here, we developed a custom three-chamber microfluidic platform and established a cortico-striato-nigral microcircuit recapitulating the striatal presynaptic triad in vitro using induced pluripotent stem cell (iPSC)-derived neurons. We found that, although cortical glutamatergic projections facilitated MSN synaptic activity, dopaminergic transmission was essential for excitability maturation of MSNs in vitro . Replacement of wild-type iPSC-dopamine neurons (iPSC-DaNs) in the striatal microcircuit with those carrying the PD-related GBA-N370S mutation induced early hyperexcitability in iPSC-MSNs through reduction of voltage-gated sodium and potassium intrinsic currents. Such deficits were resolved in aged cultures or with antagonism of protein kinase A activity in nigrostriatal iPSC-DaNs. Hence, our results highlight the unique utility of modelling striatal neurons in a modular and highly physiological circuit which is essential to reveal mechanistic insights of the loss of electrical functional integrity in the striata of GBA1 PD patients.


  • Open Access

    Tau depletion in human neurons mitigates Aβ-driven toxicity

    by Bryan Ng, Jane Vowles, Dayne Beccano-Kelly, M Irina Stefana, Darragh P. O’brien, Nora Bengoa-Vergniory, Feodora Betherat, Ajantha Abey, Philippa Carling, Peter Kilfeather, et al.

    Background: Alzheimer’s disease (AD) is an age-related neurodegenerative condition and the most common type of dementia, characterised by pathological accumulation of extracellular plaques and intracellular neurofibrillary tangles that mainly consist of amyloid-β (Aβ) and hyperphosphorylated tau aggregates, respectively. Previous studies in mouse models with a targeted knock-out of the microtubule-associated protein tau (Mapt) gene demonstrated that Aβ-driven toxicity is tau-dependent. However, human cellular models with chronic tau lowering remain unstudied. Methods: In this study, we generated stable tau-depleted human induced pluripotent stem cell (iPSC) isogenic panels from two healthy individuals using CRISPR-Cas9 technology. We then differentiated these iPSCs into cortical neurons in vitro in co-culture with primary rat cortical astrocytes before conducting electrophysiological and imaging experiments for a wide range of disease-relevant phenotypes. Both AD brain derived and recombinant Aβ were used in this study to elicit toxic responses from the iPSC- derived cortical neurons. Results: We showed that tau depletion in human iPSC-derived cortical neurons caused considerable reductions in neuronal activity without affecting synaptic density. We also observed neurite outgrowth impairments in two of the tau-depleted lines used. We found axonal transport of mitochondria, mitochondrial function, and cortical neuron differentiation propensity remained unaffected regardless of tau expression levels. Finally, tau depletion protected neurons from adverse effects mitigating the impact of exogenous Aβ-induced hyperactivity, deficits in retrograde axonal transport of mitochondria, and neurodegeneration. Conclusions: Our study established stable human iPSC isogenic panels with chronic tau depletion from two healthy individuals. Cortical neurons derived from these iPSC lines showed that tau is essential in Aβ-driven hyperactivity, axonal transport deficits, and neurodegeneration, consistent with studies conducted in Mapt-/- mouse models. These findings highlight the protective effects of chronic tau lowering strategies in AD pathogenesis and reinforce the potential in clinical settings. The tau-depleted human iPSC models can now be applied at scale to investigate the involvement of tau in disease-relevant pathways and cell types.


  • Open Access

    Neurons derived from individual early Alzheimer’s disease patients reflect their clinical vulnerability

    by Bryan Ng, Helen A Rowland, Tina Wei, Kanisa Arunasalam, Emma Mee Hayes, Ivan Koychev, Anne Hedegaard, Elena M Ribe, Dennis Chan, Tharani Chessell, et al.

    Establishing preclinical models of Alzheimer’s disease that predict clinical outcomes remains a critically important, yet to date not fully realized, goal. Models derived from human cells offer considerable advantages over non-human models, including the potential to reflect some of the inter-individual differences that are apparent in patients. Here we report an approach using induced pluripotent stem cell-derived cortical neurons from people with early symptomatic Alzheimer’s disease where we sought a match between individual disease characteristics in the cells with analogous characteristics in the people from whom they were derived. We show that the response to amyloid-β burden in life, as measured by cognitive decline and brain activity levels, varies between individuals and this vulnerability rating correlates with the individual cellular vulnerability to extrinsic amyloid-β in vitro as measured by synapse loss and function. Our findings indicate that patient-induced pluripotent stem cell-derived cortical neurons not only present key aspects of Alzheimer’s disease pathology but also reflect key aspects of the clinical phenotypes of the same patients. Cellular models that reflect an individual’s in-life clinical vulnerability thus represent a tractable method of Alzheimer’s disease modelling using clinical data in combination with cellular phenotypes.


  • Open Access

    Neurons from individual early Alzheimer’s disease patients reflect their clinical vulnerability

    by Bryan Ng, Helen A. Rowland, Tina Wei, Kanisa Arunasalam, Emma Mee Hayes, Ivan Koychev, Anne Hedegaard, Elena M. Ribe, Dennis Chan, Tharani Chessell, et al.

    Establishing preclinical models of Alzheimer’s disease that predict clinical outcomes remains a critically important, yet to date not fully realised, goal. Models derived from human cells offer considerable advantages over non-human models, including the potential to reflect some of the inter-individual differences that are apparent in patients. Here we report an approach using induced pluripotent stem cell-derived cortical neurons from people with early symptomatic Alzheimer’s disease where we sought a match between individual disease characteristics in cells with analogous characteristics in the people from whom they were derived. We show that the response to amyloid-β burden in life, as measured by cognitive decline and brain activity levels, varies between individuals and this vulnerability rating correlates with the individual cellular vulnerability to extrinsic amyloid-β in vitro as measured by synapse loss and function. Our findings indicate that patient induced pluripotent stem cell-derived cortical neurons not only present key aspects of Alzheimer’s disease pathology, but also reflect key aspects of the clinical phenotypes of the same patients. Cellular models that reflect an individual’s in-life clinical vulnerability thus represent a tractable method of Alzheimer’s disease modelling using clinical data in combination with cellular phenotypes.